VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 251 filers reported holding VAXCYTE INC in Q1 2024. The put-call ratio across all filers is 0.73 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,299,032 | -35.6% | 43,690 | -41.8% | 0.14% | -36.6% |
| Q1 2024 | $5,125,982 | -4.3% | 75,040 | -12.0% | 0.21% | -10.1% |
| Q4 2023 | $5,354,328 | +85.5% | 85,260 | +50.6% | 0.24% | +61.2% |
| Q3 2023 | $2,886,997 | -16.2% | 56,630 | -17.9% | 0.15% | -5.8% |
| Q2 2023 | $3,445,860 | – | 69,000 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $59,882,148 | 46.04% |
| Darwin Global Management, Ltd. | 2,080,946 | $163,916,116 | 19.07% |
| RA Capital Management | 8,203,754 | $619,465,465 | 8.19% |
| ACUTA CAPITAL PARTNERS, LLC | 110,400 | $8,336,304 | 7.02% |
| COMMODORE CAPITAL LP | 1,305,000 | $98,540,550 | 6.73% |
| Saturn V Capital Management LP | 215,680 | $16,285,997 | 6.15% |
| Cormorant Asset Management, LP | 1,100,000 | $83,061,000 | 4.80% |
| Kynam Capital Management, LP | 753,240 | $56,877,152 | 4.39% |
| Novo Holdings A/S | 950,000 | $71,734,500 | 4.16% |
| Frazier Life Sciences Management, L.P. | 1,039,405 | $78,485,472 | 3.67% |